S-1联合紫杉醇治疗晚期胃癌的临床疗效观察

目的评估S-1联合紫杉醇治疗晚期胃癌的疗效、不良反应和临床受益反应。方法 36例晚期胃癌患者,1-14d内给予S-1,80mg/m2,分2次口服（餐后服用）,同时在第1、8、15d紫杉醇90mg/m2。S-1用药14d停药,14d为1个周期,紫杉醇4周为1个周期。治疗2个周期后进行疗效、不良反应及临床受益反应评价。结果全组36例可评价,完全缓解0例,部分缓解24例,稳定9例,进展3例,有效率为66.7%,不良反应率较低,临床受益反应较好。结论 S-1联合紫杉醇治疗晚期胃癌患者近期疗效较好,不良反应可以耐受,临床受益反应较好。

Observation Study on Paclitaxel Plus S-1 as Therapy for Patients with Advanced Gastric Cancer

Objective Observed the short-term efficacy,side effecs and clinical benefit response on 36 patients with S-1 combined with paclitaxel.Methods To the fourteenth day of the first day,the 36 patients with advanced gastric cancer were given a set of S-1,80mg/m2,2 times orally(after meal),at the same time given paclitaxel,90mg/m2 in the first day,the eighth day and the fifteenth day.S-1 treatment for 14days,for a period 14days.Paclitaxel is for a period 4 weeks.After two cycles the patients were evaluated for cu...